HomeCompareIVME vs MRK

IVME vs MRK: Dividend Comparison 2026

IVME yields 285714.29% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVME wins by $1.734986541242196e+31M in total portfolio value
10 years
IVME
IVME
● Live price
285714.29%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.734986541242196e+31M
Annual income
$17,337,928,197,276,910,000,000,000,000,000,000,000.00
Full IVME calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — IVME vs MRK

📍 IVME pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVMEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVME + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IVME pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVME
Annual income on $10K today (after 15% tax)
$24,285,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,737,238,967,685,373,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, IVME beats the other by $14,737,238,967,685,373,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVME + MRK for your $10,000?

IVME: 50%MRK: 50%
100% MRK50/50100% IVME
Portfolio after 10yr
$8.67493270621098e+30M
Annual income
$8,668,964,098,638,455,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IVME
No analyst data
Altman Z
-205.3
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVME buys
0
MRK buys
0
No recent congressional trades found for IVME or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVMEMRK
Forward yield285714.29%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$1.734986541242196e+31M$56.8K
Annual income after 10y$17,337,928,197,276,910,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$1.734908400352195e+31M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IVME vs MRK ($10,000, DRIP)

YearIVME PortfolioIVME Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$28,582,129$28,571,428.57$11,206$366.19+$28.57MIVME
2$76,351,353,429$76,320,770,551.21$12,650$502.35+$76351.34MIVME
3$190,619,493,207,524$190,537,797,259,355.30$14,407$694.19+$190619493.19MIVME
4$444,781,927,427,195,200$444,577,964,569,463,100.00$16,585$967.82+$444781927427.18MIVME
5$969,967,353,346,567,200,000$969,491,436,684,220,000,000.00$19,342$1,363.89+$969967353346567.13MIVME
6$1,976,961,629,315,093,000,000,000$1,975,923,764,247,012,300,000,000.00$22,913$1,947.19+$1976961629315092992.00MIVME
7$3,765,923,944,594,039,000,000,000,000$3,763,808,595,650,671,000,000,000,000.00$27,662$2,823.89+$3.765923944594039e+21MIVME
8$6,704,681,437,057,684,000,000,000,000,000$6,700,651,898,436,968,000,000,000,000,000.00$34,159$4,173.35+$6.704681437057683e+24MIVME
9$11,156,275,836,497,016,000,000,000,000,000,000$11,149,101,827,359,364,000,000,000,000,000,000.00$43,337$6,308.80+$1.1156275836497015e+28MIVME
10$17,349,865,412,421,960,000,000,000,000,000,000,000$17,337,928,197,276,910,000,000,000,000,000,000,000.00$56,776$9,798.13+$1.734986541242196e+31MIVME

IVME vs MRK: Complete Analysis 2026

IVMEStock

In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.

Full IVME Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IVME vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVME vs SCHDIVME vs JEPIIVME vs OIVME vs KOIVME vs MAINIVME vs JNJIVME vs ABBVIVME vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.